Proteolix, which is developing drugs to treat cancer by disrupting key cell functions, has raised $79 million in a third round of funding, according to VentureWire. That’s the third largest biotech funding this year.

Nomura Phase4 Ventures, a new investor, led the round, with participation from new backer Westfield Capital Management and existing investors Advanced Technology Ventures, Delphi Ventures, Latterell Venture Partners, U.S. Venture Partners and Vertical Group.

The new funding should allow South San Francisco-based Proteolix to conduct Phase II and Phase III clincial trials of its lead drug, Carfilzomib.